

# Christopher S King

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8665630/christopher-s-king-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

55  
papers

3,756  
citations

15  
h-index

61  
g-index

65  
ext. papers

4,882  
ext. citations

4.4  
avg, IF

5.28  
L-index

#	Paper	IF	Citations
55	Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2016</b> , 149, 315-352	5.3	3090
54	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 72-84	35.1	97
53	Pulmonary artery size as a predictor of pulmonary hypertension and outcomes in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 1626-32	4.6	55
52	Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2021</b> , 160, e545-e608	5.3	48
51	High-Flow Nasal Cannula Therapy in COVID-19: Using the ROX Index to Predict Success. <i>Respiratory Care</i> , <b>2021</b> , 66, 909-919	2.1	37
50	Identification and treatment of comorbidities in idiopathic pulmonary fibrosis and other fibrotic lung diseases. <i>Current Opinion in Pulmonary Medicine</i> , <b>2013</b> , 19, 466-73	3	36
49	Executive Summary: Antithrombotic Therapy for VTE Disease: Second Update of the CHEST Guideline and Expert Panel Report. <i>Chest</i> , <b>2021</b> , 160, 2247-2259	5.3	35
48	Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. <i>European Respiratory Journal</i> , <b>2016</b> , 47, 1445-51	13.6	33
47	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure. <i>PLoS ONE</i> , <b>2020</b> , 15, e0242651	3.7	33
46	Practical considerations in the pharmacologic treatment of idiopathic pulmonary fibrosis. <i>Current Opinion in Pulmonary Medicine</i> , <b>2015</b> , 21, 479-89	3	30
45	Moving toward a more ideal anticoagulant: the oral direct thrombin and factor Xa inhibitors. <i>Chest</i> , <b>2013</b> , 143, 1106-1116	5.3	23
44	Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients. <i>Transplant Infectious Disease</i> , <b>2019</b> , 21, e13166	2.7	21
43	Management of right heart failure in the critically ill. <i>Critical Care Clinics</i> , <b>2014</b> , 30, 475-98	4.5	19
42	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. <i>Drug Design, Development and Therapy</i> , <b>2014</b> , 8, 875-85	4.4	19
41	The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. <i>Chest</i> , <b>2020</b> , 158, 1651-1664	5.3	15
40	Hemothorax following lung transplantation: incidence, risk factors, and effect on morbidity and mortality. <i>Multidisciplinary Respiratory Medicine</i> , <b>2016</b> , 11, 40	3	14
39	Critical Care of the Adult Patient With Cystic Fibrosis. <i>Chest</i> , <b>2019</b> , 155, 202-214	5.3	14

38	Pulmonary hypertension due to interstitial lung disease. <i>Current Opinion in Pulmonary Medicine</i> , <b>2019</b> , 25, 459-467	3	12
37	Inhaled treprostinil and forced vital capacity in patients with interstitial lung disease and associated pulmonary hypertension: a post-hoc analysis of the INCREASE study. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1266-1274	35.1	11
36	Prevalence and impact of WHO group 3 pulmonary hypertension in advanced idiopathic nonspecific interstitial pneumonia. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	11
35	Cardiac Support: Emphasis on Venoarterial ECMO. <i>Critical Care Clinics</i> , <b>2017</b> , 33, 777-794	4.5	10
34	Association of D-dimer and Fibrinogen With Hypercoagulability in COVID-19 Requiring Extracorporeal Membrane Oxygenation. <i>Journal of Intensive Care Medicine</i> , <b>2021</b> , 36, 689-695	3.3	8
33	Lung Transplantation of COVID-19 Patients. <i>Chest</i> , <b>2021</b> ,	5.3	8
32	Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. <i>Current Respiratory Care Reports</i> , <b>2012</b> , 1, 233-242		7
31	Fostamatinib for the treatment of hospitalized adults with COVID-19 A randomized trial. <i>Clinical Infectious Diseases</i> , <b>2021</b> ,	11.6	6
30	Early postoperative management after lung transplantation: Results of an international survey. <i>Clinical Transplantation</i> , <b>2017</b> , 31, e12985	3.8	5
29	The association between white blood cell count and outcomes in patients with idiopathic pulmonary fibrosis. <i>Respiratory Medicine</i> , <b>2020</b> , 170, 106068	4.6	5
28	A 24-Year-Old Woman With Precipitous Respiratory Failure After Lung Transplantation. <i>Chest</i> , <b>2018</b> , 153, e53-e56	5.3	5
27	Association Between Anticoagulation and Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation Patient Registry. <i>Chest</i> , <b>2021</b> , 159, 1507-1516	5.3	5
26	Exercise pulmonary haemodynamic response predicts outcomes in fibrotic lung disease. <i>European Respiratory Journal</i> , <b>2018</b> , 52,	13.6	4
25	Antifibrotic Therapies and Progressive Fibrosing Interstitial Lung Disease (PF-ILD): Building on INBUILD. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	4
24	HRCT evaluation of patients with interstitial lung disease: comparison of the 2018 and 2011 diagnostic guidelines. <i>Therapeutic Advances in Respiratory Disease</i> , <b>2020</b> , 14, 1753466620968496	4.9	3
23	Idiopathic Pulmonary Fibrosis: Phenotypes and Comorbidities. <i>Respiratory Medicine</i> , <b>2019</b> , 273-297	0.2	2
22	Impact of the new definition for pulmonary hypertension in patients with lung disease: an analysis of the United Network for Organ Sharing database. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 2045894021999960	2.7	2
21	Inhaled Nitric Oxide via High-Flow Nasal Cannula in Patients with Acute Respiratory Failure Related to COVID-19. <i>Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine</i> , <b>2021</b> , 15, 11795484211047065	2.4	2

20	Idiopathic pulmonary fibrosis patients with severe physiologic impairment: characteristics and outcomes. <i>Respiratory Research</i> , <b>2021</b> , 22, 5	7.3	2
19	Fungal thyroiditis in a lung transplant recipient. <i>BMJ Case Reports</i> , <b>2018</b> , 2018,	0.9	2
18	Ventricular Diastolic Pressure Ratio as a Marker of Treatment Response in Pulmonary Hypertension. <i>Chest</i> , <b>2017</b> , 152, 980-989	5.3	1
17	Does 1-minute walk test predict results of 6-minute walk test in patients with idiopathic pulmonary fibrosis?. <i>Sarcoidosis Vasculitis and Diffuse Lung Diseases</i> , <b>2021</b> , 38, e2021005	1.1	1
16	Association of D-dimer and fibrinogen magnitude with hypercoagulability by thromboelastography in severe COVID-19		1
15	Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. <i>BMC Pulmonary Medicine</i> , <b>2020</b> , 20, 191	3.5	1
14	The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1601-1609	4.7	1
13	A 70-Year-Old Woman Presenting With Diarrhea and In-hospital Cardiac Arrest. <i>Chest</i> , <b>2018</b> , 153, e5-e8	5.3	0
12	Impact of Noninvasive Respiratory Support in Patients With COVID-19 Requiring V-V ECMO.. <i>ASAIO Journal</i> , <b>2022</b> , 68, 171-177	3.6	0
11	Development and Validation of a Clinical Diagnostic Scoring System for the Diagnosis of Idiopathic Pulmonary Fibrosis. <i>Annals of the American Thoracic Society</i> , <b>2021</b> , 18, 1803-1810	4.7	0
10	Incidence and prognostic significance of pleural effusions in pulmonary arterial hypertension. <i>Pulmonary Circulation</i> , <b>2021</b> , 11, 20458940211012366	2.7	0
9	Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.. <i>Pulmonary Circulation</i> , <b>2022</b> , 12, e12055 <sup>2.7</sup>	2.7	0
8	Extracorporeal Membrane Oxygenation as a Bridge to Initial Medical Therapy in a Patient With Decompensated Pulmonary Arterial Hypertension Presenting With Biventricular Failure. <i>Journal of Medical Cases</i> , <b>2019</b> , 10, 260-263	0.2	
7	63: D-Dimer and Fibrinogen Magnitude and Hypercoagulability by Thromboelastography in Severe COVID-19. <i>Critical Care Medicine</i> , <b>2021</b> , 49, 33-33	1.4	
6	Extracorporeal life support for cardiogenic shock during pregnancy and postpartum: a single center experience. <i>Perfusion (United Kingdom)</i> , <b>2021</b> , 2676591211004369	1.9	
5	ISHLT consensus document on lung transplantation in patients with connective tissue disease: Part II: Cardiac, surgical, perioperative, operative, and post-operative challenges and management statements. <i>Journal of Heart and Lung Transplantation</i> , <b>2021</b> , 40, 1267-1278	5.8	
4	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure <b>2020</b> , 15, e0242651		
3	Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure <b>2020</b> , 15, e0242651		

2 Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure **2020**,  
15, e0242651

1 Outcomes of mechanically ventilated patients with COVID-19 associated respiratory failure **2020**,  
15, e0242651